Saturday March 25

16:40-17:00: Welcome and Welcome lecture (Room A)

Diversity and Integration of Vasculitis

Chairs: Toshihiko Nagasawa & Shouichi Fujimoto

16:40-17:00 W, WL: Yoshihiro Arimura

17:00-18:00: Fokko Van Der Woude Lecture (Room A) ANCA-ASSOCIATED VASCULITIDES: FUTURE THERAPEUTIC STRATEGIES Chairs: Kazuo Suzuki & Charles Pusey

17:00-18:00 Wounde Lecture: Loic Guillevin "ANCA-ASSOCIATED VASCULITIDES: FUTURE THERAPEUTIC STRATEGIES"

18:00-20:00: Welcome Reception (Exhibition)

	Sunday !	March 26	
	09:00-11:20: Symp Classification of AAV: clinical Chairs: John L. Nile	entity vs a	utoantibody profile
09:00-09:35	SY1-1: Ronald Falk "Classification of AAV Clinical Entity vs.	09:35-10:10	SY1-2: Ken Smith "Genetic studies in ANCA-associated
03-00 03-55	Autoantibody Profile"	00.00 10.10	vasculitis point to a new, practical disease classification based o autoantibody specificity."
10:10-10:35	SY1-3 : Naoyuki Tsuchiya "Insights from the Genetics of ANCA-associated Vasculitis in Japan."	10:35-11:00	SY1-4 : Jan Willem Cohen Tervaert "Classification of ANCA-associated vasculitis: Clinical entity versus autoantibody profile"
11:00-11:20	SY1-5 : Yoshinori Komagata "Comparison of clinical features between MPO-ANCA- and PR3-ANCA-positive AAV in Japanese patients"		
	10:10-11:20: Wor	kshop 1 (Ro	oom B)
	ANCA and Oth		
	Chairs: Shunsuke Fur	ruta & Yasu	aki Aratani
10:10-10:20	WS1-1 : Parameswaran Nair "Sputum Anti-neutrophil Cytoplasmic Antibodies (ANCA) in Eosinophilic Granulamatosis and Polyangiitis (eGPA) "	10:20-10:30	WS1-2 : Shunya Uchida "Clinical Significance of the Existence of Anti-Moesin Antibody in Systemic Vasculitides"
10:30-10:40	WS1-3 : Meghan Jobson "Immunosignature profiling of patients with ANCA vasculitis reveals novel patterns associated with disease activity and drug-associated disease"	10:40-10:50	WS1-4 : Divi Cornec "Detection of Circulating PR3-Specific B Cells in Patients with ANCA-Associated Vasculitis and Their Association with Disease Activity"
10:50-11:00	WS1-5 : Benjamin Wilde "GRANZYME B PRODUCING B-CELLS HAVE IMMUNOREGULATORY FUNCTION AND ARE DIMINISHED IN PATIENTS WITH ANCA-VASCULITIS"	11:00-11:10	WS1-6 : Luc Mouthon "Skewed peripheral B and T lymphocytes compartments in patients with ANCA associated vasculitis"
11:10-11:20	WS1-7 : Anouk von Borstel "Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients"		
	11:30-12:30: Case I	Discussion (Room A)
	Chairs: Charles Je		
11:30-11:50	CD-1 : Shigeto Kobayashi "Large-vessel Giant cell arteritis: a report of three cases" Commentator : Maria Cid	11:50-12:10	CD-2 : Shuichiro Endo "Histological sign of smoldering ANCA-associated nephritis years before burst of RPGN in two cases of IgA nephropathy" Commentator : Franco Ferrario
12:10-12:30	CD-8 : Akiko Hoshino "Relapse of pulmonary hemorrhage in a patient with pulmonary-renal syndrome with a sequential rise in MPO-ANCA and anti-GBM antibody levels" Commentator : Vladimir Tesar		
	12:40-13:40: Luncheo	n Seminar	1 (Room A)
	Chair: Yoshi Sponsored by CHUGAI PHA		
12:40-13:40	LS1: David Jayne "Role of Rituximab in the current treatment of ANCA associated vasculitis"		

	12:40-13:40: Lunchee Chair: Hiro	on Seminar : ofumi Makin	
	Sponsored by NIP		
2:40-13:40	LS2: Maarten Segelmark "1st, 2nd and 3rd generation of ANCA testing"		
	13:50-15:55: Sym	posium 2 (R	oom A)
	Kawasaki Disease: hist Chairs: Seza Oze		
13:50-14:25	SY2-1: Tomisaku Kawasaki "Recognition of Kawasaki Disease"	14:25-14:50	SY2-2 : Yoshikazu Nakamura "Epidemiologic features of Kawasaki disease and lessons from them"
14:50-15:15	SY2-3 : Yoshihiro Onouchi "Genetic factors of Kawasaki Disease"	15:15-15:40	SY2-4 : Tohru Kobayashi "Acute management of Kawasaki disease"
15:40-15:55	SY2-5: Hideyuki Nakaoka "MicroRNA-145-5p and		
	microRNA-320a upregulate inflammatory cytokine expression		
	levels and contribute to the progression of vasculitis in acute Kawasaki Disease."		
	14:30-15:20: Wor	rkshop 2 (Ro miology	om B)
	Chairs: Maarten Segel		fumi Makino
14:30-14:40	WS2-1: Raaashid Luqmani "The UK & Ireland Vasculitis	14:40-14:50	WS2-2 : Nishkantha Arulkumaran "Outcomes in
	Registry (UKIVAS): Cross-sectional data on the first 2290		ANCA-Associated Vasculitis - a 40 Year Retrospective Cohort
	Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)"		Study"
14:50-15:00	WS2-3 : Zdenka Hruskova "Chronic Damage in Patients with ANCA-Associated Vasculitis: Data from a National Registry"	15:00-15:10	WS2-4 : Mara Felicetti "Change of Perspective: Anca Pattern Based Analisys in Granulomatosis with Polyangiitis and Microscopic Polyangiitis."
15:10-15:20	WS2-5 : Nobuyuki Ono "Characteristics of MPO-ANCA positive GPA comparing to PR3-ANCA positive GPA and MPA."		
	15:25-15:55: Wor	rkshop 3 (Ro	om B)
		netics	m 1:
	Chairs: Ronald Fall		•
15:25-15:35	WS3-1 : Toshiki Nakajima "The Synergistic Effects of HLA-B*52	15:35-15:45	WS3-2 : Joshua Ooi "In Anti-GBM Disease, HLA-Peptide
	and Risk Allele at a SNP in IL12B Region on Complication of Aortic Regurgitation in Patients with Takayasu Arteritis"		Conformation Determines Susceptibility or Protection from Disease"
15:45-15:55	WS3-3: Peter Merkel "Identification of Functional and		Disease
10.40 10.00	Expression Polymorphisms Associated with Risk for		
	Anti-Neutrophil Cytoplasmic Autoantibody-Associated		
	Vasculitis"		
	16:30-17:30: P P1-1–	oster 1 (Post –P1-185	zers)
	18:00-19:00: Eveniu		(Poom B)
	Chair: Masa	0	
	Sponsored by CHUGAI PH		
18:00-19:00	ES : Yoshikazu Nakaoka "Update on Large Vessel Vasculitis		
	~Pathogenesis, Diagnosis and Treatment~"		
	Monday	March 27	
	09:00-11:20: Sym Pulmonary-limited MPA: a n Chairs: Ulrich Spe	new entity of	MPO-AAV or not?
09:00-09:35	SY3-1: Keishi Sugino "Clinical characteristics of	09:35-10:00	SY3-2 : Charles Pusey "PULMONARY INVOLVEMENT IN
40.00.17	pulmonary-limited microscopic polyangiitis"		MICROSCOPIC POLYANGIITIS"
10:00-10:25	SY3-3: Yasuyuki Kurihara "Pulmonary Imaging of Microscopic	10:25-10:50	SY3-4: Tamiko Takemura "Pathologic features of
	Polyangiitis"		myeloperoxidase anti-neutrophil cytoplasmic antibody positive
			interstitial pneumonia in comparison with idiopathic pulmonary
			fibrosis: New insight into the cystic lesions"
10:50-11:15	SY3-5 : Luis Felipe Flores-Suarez "Pulmonary-limited MPA: a	11:15-11:30	SY3-6 : Takeshi Saraya "Pulmonary involvement in
10:50-11:15	SY3-5 : Luis Felipe Flores-Suarez "Pulmonary-limited MPA: a new entity of MPO-AAV or not?"	11:15-11:30	

	09:40-10:30: Wor Molecular and Ce I	-	
	Chairs: Peter Heeri		
09:40-09:50	WS4-1 : Veronique Witko-Sarsat "Role of the cyclin-dependent inhibitor p21/waf1 in proteinase 3-induced macrophage activation"	09:50-10:00	WS4-2 : Judith Everts-Graber "Proteomic analysis of neutrophil from GPA demonstrates a dysregulation in apoptotic pathways and a defect in annexin-A1-mediated anti-inflammatory mechanisms"
10:00-10:10 10:20-10:30	 WS4-3: Scott Henderson "Proteinase-3 (PR3) Auto-antigen Drives Giant Cell and Granuloma Formation in ANCA-Associated Vasculitis (AAV)" WS4-5: Su-Fang Chen "Myeloperoxidase Influences the Complement Regulatory Activity of Complement Factor H" 	10:10-10:20	WS4-4 : Lucas Lintermans "Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis "
	10:35-11:25: Wor	kshop 5 (Ro	om B)
	TAK, GC A Chairs: Elisabeth Bro	, KD, PAN uwer & Kei	Takahashi
0:35-10:45	WS5-1 : Fatma Alibaz-Oner "Assessment of the Frequency of	$10:45 \cdot 10:55$	WS5-2: Yoshikazu Nakaoka "Efficacy and Safety of
	Cardiovascular Risk Factors in Patients with Takayasu Arteritis "		Subcutaneous Tocilizumab in Japanese Patients with Refractor Takayasu Arteritis: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial"
0:55-11:05	WS5-3 : Matthew Koster "Differences in Presentation and Outcome in Patients with Giant Cell Arteritis Based on	11:05-11:15	WS5-4 : Tamihiro Kawakami "Relationship of anti-phosphatidylserine-prothrombin complex antibodies and
1:15-11:25	Temporal Artery Biopsy Positivity" WS5-5 : Yoshiro Kitagawa "Increased levels of plasma pentraxin 3 predict IVIG resistance and coronary artery lesion formation in patients with Kawasaki disease"		anti-moesin antibodies in patients with polyarteritis nodosa"
	11:50-12:50: Luncheo		
	Chair: Shou Sponsored by Zeny		
11:50-12:50	LS3: John Stone "Achieving and Maintaining Remission in AAV:What are we missing?"	and Hogyo	
	11:50-12:50: Luncheo	n Seminar 4	(Room B)
		bisease	
	Chair: Masa Spongoord by Mitaubishi T		
1:50-12:20	Sponsored by Mitsubishi T L84-1: Annabelle Okada "Behcet's disease ; Ocular	12:20-12:50	
.1.00*12.20	Manifestations and Advances in Treatment"	12.20.12.30	LS4-2 : Shunsei Hirohata "Recalcitrant complications of Behcet" Disease"
	13:00-15:30: Symj TAK and GCA: a spectrum w Chairs: Peter Merke	ithin the sa	me disease or not?
13:00-13:35	SY4-1 : Raashid Luqmani "Giant cell arteritis (GCA) and Takayasu arteritis (TAK): a spectrum within the same disease or	13:35-14:00	SY4-2 : Tanaz Kermani "Takayasu arteritis and Giant Cell Arteritis: A Spectrum Within the Same Disease or Not? Review
4:00-14:25	not? A report from the DCVAS project." SY4-3 : Yasuhiro Maejima "TXNIP accumulation caused by single nucleotide polymorphism of MLX gene enhances inflammasome formation, thereby promoting the development of Takayasu arteritis"	14:25-14:50	of Epidemiological and Clinical aspects." SY4-4 : Carol Langford "Takayasu's Arteritis and Giant Cell Arteritis: A Spectrum Within the Same Disease or Not?"
4:50-15:15	SY4-5 : David Saadoun "The roles of cytokines in the pathogenesis of TAK and GCA"	15:15-15:30	SY4-6 : John Stone "Efficacy and Safety of Tocilizumab in Patier Subgroups With New-Onset and Relapsing Giant Cell Arteritis From a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial"

	13:40-14:50: Wor Molecular and Cel	-	
	Chairs: Alan Salama	& Junichi	
13:40-13:50	WS6-1 : Peiqi Hu "Anti-MPO antibodies cause granulomatosis in mice: an animal model of GPA"	13:50-14:00	WS6-2 : Adrian Schreiber "Neutrophil-gelatinase associated lipocalin (NGAL) attenuates ANCA-induced glomerulonephritic by inhibiting Th17 immunity"
14:00-14:10	WS6-3 : Kim Maree O'Sullivan "Deoxyribonuclease I Reduces Glomerular Injury and Modulates anti-Myeloperoxidase Autoimmunity in Experimental anti Myeloperoxidase Glomerulonephritis"	14:10-14:20	WS6-4 : Holly Hutton "Targeting the NLRP3 Inflammasome in ANCA Vasculitis"
4:20-14:30	WS6-5: Mira Choi "Endothelial NF-kB Blockade by E-selectin Targeted Liposomes Containing P65 SiRNA Abrogates Anti-MPO Antibody-induced Glomerulonephritis" WS6-7: Yusuke Nishioka "Rat type II NKT cell clone pathogenic	14:30-14:40	WS6-6 : Megan Huynh "HLA-DR15 Inhibition Attenuates Experimental Autoimmune Anti-Glomerular Basement Membrane Disease"
	for small vessel vasculitis recognizes sterol carrier protein 2."		
	14:55-15:30: Wor QOL and Hea		
	Chairs: Min Chen		
14:55-15:05	WS7-1: Maria Weiner "Organ Damage and Hospitalization in	15:05-15:15	WS7-2: Christian Pagnoux "Impact of Vasculitis on Employmer
	Elderly Patients with Anti-Neutrophil Cytoplasmic Antibody		and Income"
	(ANCA)-Associated Vasculitis"		
15:15-15:25	WS7-3 : Loic Guillevin "Economic evaluation of rituximab versus		
	azathioprine for maintenance treatment of ANCA-associated vasculitis: the MAINRITSAN trial"		
	16:00-17:00: Pc		zers)
		-P2-177	·
	19:00-21:00: GALA Dinna	r (Hotel Ch	inzanso Tokyo)
	-	March 28	<u>`</u>
	09:00-10:50: Symp Beheet	posium 5 (R Disease	oom A)
	Chairs: Eric Matteson		ri Takasaki
09:00-09:35	SY5-1: Nobuhisa Mizuki "Genome-wide association study for Behcet's disease"	09:35-10:00	SY5-2 : Alfred Mahr "MHC class I antigen and Behçet's disease
10:00-10:25	SY5-3 : Mitsuhiro Takeno "Vascular involvement of Behçet's disease"	10:25-10:50	SY5-4 : Shunsei Hirohata "Neurological involvement in Behçet' disease"
	09:40-10:50: Wor	-	
	Head and Neck Involveme Chairs: Tamihiro Kawaka		
09:40-09:50	WS8-1: Kan Kishibe "Otitis media with ANCA-associated	09:50-10:00	WS8-2: Yuka Morita "Otitis Media with ANCA-associated
	vasculitis (OMAAV): A retrospective multicenter study in Japan, Clinical findings."		Aasculitis (OMAAV): A Retrospective Multi-center Study in Japan, Clinical feature of the OMAAV Patients with Facial Nerve Palsy and/or Hypertrophic Pachymeningitis"
10:00-10:10	WS8-3 : Kaori Tateyama "Clinical differences of otitis media with ANCA-associated vasculitis based on the type of ANCAs: a retrospective multi-center study in Japan"	10:10-10:20	WS8-4 : Naohiro Yoshida "Audiological Findings and Outcome after Immunosuppressive Therapy in Otitis Media with ANCA-associated Vasculitis (OMAAV): A Retrospective Multi-center Study in Japan"
10:20-10:30	WS8-5 : Ashima Makol "Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic	10:30-10:40	WS8-6 : Pavel Novikov "Venous Thrombotic Events in Patients with ANCA-Positive Vasculitides"
0:40-10:50	Antibody-Associated Vasculitis: A Retrospective Cohort Study" WS8-7 : Charles Pusey "ANCA-Associated Vasculitis is Associated with a High Rate Of Arterial and Venous Thrombosis"		
	11:00-12:00: Specia		
	Control of immune respo	nses by reg	ulatory T cells
	Chairs: Wolfgang Gros		•

	12:20-13:20: Lunche	on Seminar !	5 (Room A)
		tihiro Ishizu	
	Sponsored by TEIJI	N PHARMA	LIMITED
12:20-12:50	LS5-1: Takashi Kanda	12:50-13:20	LS5-2: Tsutomu Saji
	12:20-13:20: Lunched		
		niko Ito-Ihar	
0.00 10.00	Sponsored by Thermo	Fisher Diag	mostics K.K.
12:20-13:20	LS6 : Xavier Bossuyt "New paradigm for ANCA detection in vasculitis."		
	13:30-15:25: Sym		
	New drugs and Ongoing		
	Chairs: Yoshihiro Arim		
13:30-14:05	SY6-1 : Michael Walsh	14:05-14:30	SY6-2: Rona Smith "Mepolizumab for the treatment of
		1.4.88 18410	eosinophilic granulomatosis with polyangiitis."
14:30-14:55	SY6-3 : Loic Guillevin "New therapeutic approaches in	14:55-15:10	SY6-4 : Benjamin Terrier "Rituximab Versus Azathioprine to
	eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"		Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-Up At 60 Months"
15:10-15:25	SY6-5 : Janneke Tuin "Mycophenolate mofetil versus		(MAINTISAN). Follow Op At 60 Months
10.10 10.20	Cyclophosphamide for the Induction of Remission in		
	Non-life-threatening Relapses of PR3 and MPO-ANCA		
	Associated Vasculitis"		
	14:10-15:20: Wo	rkshon 9 (Re	pom B)
	Renal Pathology, Cla	-	
	Chairs: Ingeborg Ba		
4:10-14:20	WS9-1 : Emma van Daalen "International Validation Study for	14:20-14:30	WS9-2: Yayoi Ogawa "Pathological Analysis on the Role of Sma
	the Histopathological Classification of ANCA-Associated		Vessel Vasculitis and Tubulo-interstitial Lesions in
	Glomerulonephritis (AAGN)"		ANCA-associated Nephritis"
14:30-14:40	WS9-3 : Tomomi Endo "Reevaluation of Combining Chronic	14:40-14:50	WS9-4 : Noriko Uesugi "What glomerular morphology causes
	Tubulo-interstitial Parameters on the Glomerular Histological		interobserver disagreement?"
	Classification to Predict the Long Term Outcome in Japanese		
	Cohort of MPO-ANCA Associated GN"		
14:50-15:00	WS9-5 : Layla Alharbi "Prevalence of Immunofluorescent	15:00 15:10	WS9-6 : Gerjan Dekkema "Combined Measurement Of Urinary
	Deposits in ANCA Associated Vasculitis"		sCD25 And sCD163 As Biomarker For Active ANCA Associated
15:10-15:20	WS9-7 : Sarah Moran "Utility of Measurements of Urinary		Renal Vasculitis"
10.10 10.20	Soluble CD163 & MCP1 in the Identification of Subtle Renal		
	Flares in ANCA Vasculitis"		
	15:30-16:25: Closi	(1	$\mathbf{D}_{\mathbf{r}}$
	Ongoing and Futu	0 .	
	Chairs: David Jayne		
15:30-15:45	CS-1: Elena Csernok "Revised international consensus	15:45-16:00	CS-2: Masayoshi Harigai "A clinical trial of tocilizumab for
	recommendation on testing of anti-neutrophil cytoplasm		microscopic polyangiitis and granulomatosis with polyangiitis"
	antibodies (ANCA) in small vessel vasculitis: evaluation of		
	ANCA testing by antigen specific assays"		
16:00-16:25	CS-3: Peter Merkel "Current and Future Clinical and		
	Translational Research Studies in Vasculitis"		
	16:25-16:30: Closin	g Remarks	(Room A)
	Acknowledgements and In		
	Chairs: David Jayne	e & Shouichi	i F'ujimoto
16:25-16:30	CR : Yoshihiro Arimura		